SMML, our Monthly Newsletter dedicated to Multiple Myeloma

The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting on new developments on the other hand.



Who will benefit from this newsletter? 

Any professionals interested in keeping up with developments around multiple myeloma:

      • Marketers
      • Business Analysts
      • But also HCPs who want to anticipate the future landscape of MM management


The scope of the analysis is focused on mentions coming worldwide.*

There were a total of 49K mentions from patients recorded during the listening period from January 1st, 2023, to February 28th, 2023

A majority of mentions came from News (43%), Twitter (39%), Instagram (12%), Forums (2%), Reddit (2%), Tumblr (1%) and blogs (1%).

A total of 12K unique authors were identified.

*: Myeloma OR multiplemyeloma OR #Mmsm OR #Myeloma* OR #Curemyeloma* OR #Mmmrd OR #mmsm OR title: ("multiple myeloma" OR myeloma)





Some extracts from the multiple myeloma monthly newsletter 

Hot off the press

    FDA Grants Priority Review to Elranatamab in Relapsed/Refractory Myeloma

“The FDA has granted a priority review to the biologics license application for elranatamab for the treatment of patients with relapsed/refractory multiple myeloma.”  
Click here to read the full article



Media: volume and articles per peak

Volume of articles overtime

A “NHS spending watchdog approves three-drug treatment which lets blood cancer patients live longer - potentially helping 6,000 Britons with multiple myeloma a year Link

“Inflammatory-Nutritional Score Helps Predict Survival in New Multiple Myeloma” Link

“Body Mass Index Tied to Multiple Myeloma Survival” Link

“Takeda’s Ninlaro (ixazomib) Receives NICE Recommendation for the Treatment of Multiple Myeloma” Link

B Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma” Link​ 

C Alternative To Lenalidomide ID’d For Maintenance In Multiple Myeloma” Link

D Karyopharm and Menarini Receive Full Marketing Authorization from the UK MHRA for NEXPOVIO (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy” Link

E “Ide-Cel Beneficial in Relapsed, Refractory Multiple Myeloma”​ Link

F Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma” Link


Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma” Link



Drug Market Watch​

January - February 2023

Sans titre (9)-1


Fill this short form to discover the entire newsletter
and to receive next SMML newsletters directly in your mailbox!
👇 👇